Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience
By:
References
- Diop S, Haffar A, Mahlangu J, et al. Improving access to hemophilia care in sub-Saharan Africa by capacity building.
Blood Adv 2019; 3(Suppl 1): 1–4. doi:10.1182/bloodadvances.2019GS121537 . - Ndoumba-Mintya A, Diallo YL, Tayou TC, Mbanya DN. Optimizing haemophilia care in resource-limited countries: current challenges and future prospects.
J Blood Med 2023; 14: 141–6. doi:10.2147/JBM.S291536 . - Pierce GF, Adediran M, Diop S, Dunn AL, El Ekiaby M, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years.
Lancet Haematol 2022; 9(9): e689–e97. doi:10.1016/S2352-3026(22)00209-5 . - Blair HA. Emicizumab: A review in haemophilia A. Drugs 2019; 79(15): 1697–707. doi:
10.1007/s40265-019-01200-2 . - Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors.
N Engl J Med 2017; 377(9): 809–18. doi:10.1056/NEJMoa1703068 . - Callaghan MU, Negrier C, Paz-Priel I, Chang T, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies.
Blood 2021; 137(16): 2231–42. doi:10.1182/blood.2020009217 . - Warren BB, Chan A, Manco-Johnson M, et al. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report.
Res Pract Thromb Haemost 2021; 5(5): e12571. doi:10.1002/rth2.12571 . - Arcudi S, Gualtierotti R, Marino S, et al. Real-world data on emicizumab prophylaxis in the Milan cohort.
Haemophilia 2022; 28(5): e141–e144. doi:10.1111/hae.14630 . - Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab.
J Clin Med 2021; 10(19): 4303. doi:10.3390/jcm10194303 . - Liu G, Huang K, Li G, et al. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China.
Front Pediatr 2022; 10: 992267. doi:10.3389/fped.2022.992267 . - Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update.
Haemophilia 2022; 28 Suppl 4(Suppl 4): 103–10. doi:10.1111/hae.14524 . - Lambert C, Meité N'D, Kouassi GK, et al. Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast.
Res Pract Thromb Haemost 2022; 7(1): 100033. doi:10.1016/j.rpth.2022.100033 . - Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data.
Br J Haematol 2020; 19(2): 282–90. doi:10.1111/bjh.16964 . - Li A, Goodfriend C, Sokol J, Kruse-Jarres R. Patterns and predictors of emicizumab adherence in people with hemophilia.
Blood 2019; 134(Supplement 1): 128083. doi:10.1182/blood-2019-128083 . - Schrijvers LH, Beijlevelt-van der Zande M, Peters M, Lock J, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study.
Br J Haematol 2016; 174(3): 454–60. doi:10.1111/bjh.14072 . - Okolo A, Shapiro A, Janson I, et al. Psychometrics and applications of a novel self-report measure of emicizumab adherence: VERITASNexGen.
Haemophilia 2023; 29(5): 1299–1305. doi:10.1111/hae.14851 .
DOI: https://doi.org/10.2478/jhp-2025-0005 | Journal eISSN: 2055-3390
Language: English
Page range: 15 - 22
Published on: Mar 19, 2025
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2025 Rebbecca Wughanga Mwakichako, Rajabu Hussein Mnkugwe, Clara Chamba, Peter Kunambi, Martha Bruckman, Anna Schuh, Michelle Munroe, Gladys Kaaya, Mwashungi Ally, Ahlam Nasser, William Mawala, Magdalena Lyimo, Johnny Mahlangu, Stella Rwezaula, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.